Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
暂无分享,去创建一个
Hing Y Leung | David E Neal | C. Robson | H. Leung | Kalipso Halkidou | Luke Gaughan | Susan Cook | Craig N Robson | L. Gaughan | Susan Cook | D. Neal | K. Halkidou | Kalipso Halkidou
[1] S. Schreiber,et al. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.
[2] T. Heinzel,et al. Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.
[3] V. Speights,et al. The dedifferentiation of metastatic prostate carcinoma. , 1989, British Journal of Cancer.
[4] S. Parodi,et al. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer , 2000, Journal of cellular biochemistry.
[5] J. Davie,et al. Rapid Induction of Histone Hyperacetylation and Cellular Differentiation in Human Breast Tumor Cell Lines following Degradation of Histone Deacetylase-1* , 2000, The Journal of Biological Chemistry.
[6] P. Brawn. Histologic features of metastatic prostate cancer. , 1992, Human pathology.
[7] N. Fusenig,et al. Differentiation and tumor progression. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[8] R. Dahiya,et al. Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.
[9] J. Swinnen,et al. Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP , 1994, Molecular and Cellular Endocrinology.
[10] E. Wintersberger,et al. Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.
[11] P G Pelicci,et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.
[12] J. McNeal,et al. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. , 1990, The Journal of urology.
[13] T. H. van der Kwast,et al. Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.
[14] U. Weidle,et al. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. , 2000, Anticancer research.
[15] R. James,et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. , 1997, Cancer research.
[16] K. Kuchler,et al. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene , 1997, Molecular and cellular biology.
[17] D. O’Carroll,et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.
[18] L. Grochow,et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] T. Ekström,et al. The human histone deacetylase family. , 2001, Experimental cell research.
[20] J. Schalken,et al. Expression of basal cell keratins in human prostate cancer metastases and cell lines , 2001, The Journal of pathology.
[21] J. Swedlow,et al. A workingperson's guide to deconvolution in light microscopy. , 2001, BioTechniques.
[22] J. Cheville,et al. Dedifferentiation in the metastatic progression of prostate carcinoma , 1999, Cancer.
[23] T. Kouzarides,et al. Regulation of E2F1 activity by acetylation , 2000, The EMBO journal.
[24] S. Schwartz,et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.
[25] J. Arends,et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low‐turnover tumors with distinct clinical outcome , 2003, Cancer.
[26] Ahmedin Jemal,et al. Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.
[27] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] S. Schwartz,et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.
[29] C. Britten,et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] A. Bird,et al. Histone deacetylases: silencers for hire. , 2000, Trends in biochemical sciences.
[31] C. Allis,et al. Roles of histone acetyltransferases and deacetylases in gene regulation , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[32] W. D. Cress,et al. Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.
[33] J. Schalken,et al. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis , 2001, BJU international.
[34] David E Neal,et al. Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor* , 2002, The Journal of Biological Chemistry.
[35] W. Fair,et al. Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancer , 1992, The Prostate.
[36] M. Nap,et al. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry. , 2000, Gynecologic oncology.
[37] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[38] G. Clark,et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. , 2001, Cytometry.
[39] Julie A Hong,et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. , 2001, The Annals of thoracic surgery.
[40] D. Neal,et al. Regulation of FGF8 expression by the androgen receptor in human prostate cancer , 2002, Oncogene.
[41] T. H. van der Kwast,et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.
[42] O. Cussenot,et al. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. , 1997, European journal of cancer.
[43] J. Isaacs. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. , 1997, The American journal of pathology.
[44] R. Nagle,et al. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. , 1987, Cancer research.
[45] C. Tei,et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. , 2002, International journal of cancer.
[46] M. Southey,et al. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.
[47] R A Rifkind,et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.
[48] S. Minucci,et al. Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO , 1998, Molecular and Cellular Biology.
[49] Brian H. Mayall,et al. Guidelines for implementation of clinical DNA cytometry , 1993 .
[50] Delin Chen,et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.
[51] A. Norton,et al. Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.
[52] J. Schalken,et al. Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy , 2000, Laboratory Investigation.
[53] K. Resing,et al. Phosphatase Inhibition Leads to Histone Deacetylases 1 and 2 Phosphorylation and Disruption of Corepressor Interactions* , 2002, The Journal of Biological Chemistry.
[54] Michael J Thun,et al. Long‐term trends in cancer mortality in the United States, 1930–1998 , 2003, Cancer.
[55] P. Brawn,et al. Stage D1 prostate carcinoma the histologic appearance of nodal metastases and its relationship to survival , 1990, Cancer.
[56] H. Kwon,et al. Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.
[57] R. Schiltz,et al. A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program , 2001, The EMBO journal.